Whilst an expert panel recently proposed cut-offs to enable separating pure SRC-GC (≥ 90% SRCs) from GC with an SRC component, a biomarker to unequivocal identify SRC-GC would be of potential great value to clinicians and patients. Here, SRC is linked to gastric cancer.